Khartis targets oral IGF-1R TED pill after $95M fundraising
Khartis Therapeutics, led by former XinThera executives after Gilead’s acquisition, emerged with a $50M Series B (total funding now $95M) to push an oral IGF-1R inhibitor for thyroid eye disease into clinical trials in Q1 2027, aiming to replace IV therapies like Tepezza and Lumvoa; the company also has other internal programs and strong investor backing.